Hormone treatment–related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

Saved in:
Bibliographic Details
Published in:European urology 2021-06, Vol.79, p.S1740-S1741
Main Authors: Fizazi, K., Shore, N., Smith, M., Carles, J., Lebret, T., Lietuvietis, V., Mahammedi, H., Rannikko, A., Vjaters, E., Werbrouck, P., Miskic, M., Kuss, I., Le Berre, M., Borghesi, G., Sarapohja, T., Fayerabend, S.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0302-2838
DOI:10.1016/S0302-2838(21)01597-9